GlassScriptPhysician profile
Edward R Rensimer
NPI 1326043654
$3,785.90
in general payments reported to CMS, 2019-2025
20 companies · $306 in 2025
The $306 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $357 · 2021: $538 · 2022: $994 · 2023: $653 · 2024: $439 · 2025: $306.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,372 · Education: $25.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.14 |
| Education | $25.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,172.29 | 2019-2025 | Biktarvy |
| Cumberland Pharmaceuticals, INC. | $393.09 | 2021-2022 | |
| Abbvie INC. | $309.08 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $245.80 | 2021-2025 | Delstrigo, Zerbaxa, Pifeltro |
| Janssen Pharmaceuticals, INC | $239.04 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $218.03 | 2022-2023 | Opsumit, Uptravi |
| E.R. Squibb & Sons, L.L.C. | $194.35 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $191.28 | 2019-2023 | Nuzyra |
| Viiv Healthcare Company | $144.65 | 2019-2023 | Dovato |
| Amarin Pharma, INC. | $118.24 | 2020 | |
| Astellas Pharma US INC | $106.12 | 2019-2021 | |
| Shionogi INC | $96.65 | 2020-2021 | |
| La Jolla Pharmaceutical Company | $91.27 | 2021-2025 | Zevtera |
| Tetraphase Pharmaceuticals, INC. | $67.62 | 2019 | |
| Insmed, INC. | $54.03 | 2019-2025 | Arikayce |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $45.31 | 2023 | Symtuza |
| Allergan, INC. | $35.30 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $28.20 | 2024 | |
| Dynavax Technologies Corporation | $23.92 | 2020 | |
| Mayne Pharma Commercial LLC | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Rensimer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.